title: Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
abstract: BACKGROUND
  Lymphomatoid papulosis (LyP) is a CD30(+) lymphoproliferative disorder, with a self-regressing clinical course and malignant histopathology.
  
  
  OBJECTIVE
  The aim of this study was to evaluate characteristics, risk factors, associated malignancies, long-term outcome, and treatment of LyP in a large cohort representing the experience of the MD Anderson Cancer Center.
  
  
  METHODS
  Patient charts and clinical and histopathologic data of 180 patients with LyP were retrospectively assessed.
  
  
  RESULTS
  A total of 56.7% of patients was men. Histologic subtype A was found in 47.2%, type B in 17.2%, type C in 22.8%, type D in 7.8%, type E in 0.6%, and mixed subtype in 4.4% of the patients. One hundred fourteen lymphomas were observed in 93 patients, with mycosis fungoides (61.4%) and anaplastic large cell lymphoma (26.3%) being the most common forms. Risk factors for development of lymphoma included sex and histologic subtype. Number of lesions and symptom severity were not associated with lymphoma development. Patients with type D were less likely to have lymphomas. Treatment provided symptomatic relief but did not prevent progression to lymphoma.
  
  
  CONCLUSIONS
  The limitation of this study is the retrospective study design.
  
  
  CONCLUSIONS
  Patients with LyP are at increased risk of associated lymphomas. Thorough patient counseling is needed and long follow-up periods are required to detect and treat secondary lymphomas.
authors.affiliation: Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas; Department of Dermatology, Paracelsus Medical University, Salzburg, Austria. Electronic address: iris.wieser@hotmail.com.
authors.forename: Iris
authors.initials: I
authors.lastname: Wieser
authors.affiliation: Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
authors.forename: Chee Won
authors.initials: CW
authors.lastname: Oh
authors.affiliation: Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
authors.forename: Rakhshandra
authors.initials: R
authors.lastname: Talpur
authors.affiliation: Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D002173:Cancer Care Facilities; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D008223:Lymphoma / Q000150:complications / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D017728:Lymphoma, Large-Cell, Anaplastic / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D017731:Lymphomatoid Papulosis / Q000150:complications / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D010789:Phototherapy / Q000379:methods; D012189:Retrospective Studies; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D013781:Texas; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents
keywords: CD30(+) lymphoproliferative disorders; associated lymphomas; cutaneous T-cell lymphoma; lymphomatoid papulosis; lymphomatoid papulosis treatment